On January 20, 2026, Jesy Nelson, the former Little Mix star, appeared on This Morning to discuss her twin daughters’ recent diagnosis of Spinal Muscular Atrophy (SMA) Type 1. This rare genetic condition affects motor function and could potentially prevent her daughters, Ocean Jade and Story Monroe Nelson-Foster, from ever walking. Jesy expressed her devastation and shared the challenging journey they faced leading up to the diagnosis, which came after several months of consultations and tests following their premature birth in May last year. She highlighted the lack of awareness surrounding this condition and her desire for enhanced newborn screening protocols in hopes that more families can be spared the anguish she is experiencing. In speaking with Wes Streeting, the health secretary, Jesy urged for urgent action and shared his emotional response to her story, bringing attention to the substantial impact that newborn screening for SMA could have on future families dealing with similar challenges. Jesy’s testimony shed light on the severe implications of SMA Type 1, which affects approximately one in 14,000 births annually. Giles Lomax, CEO of Spinal Muscular Atrophy UK, explained that SMA is characterized by the loss of motor function and varying degrees of disability, with Type 1 typically diagnosed in infants who exhibit weak muscle tone and difficulties in essential bodily functions. This highlights the chronic health struggles related to SMA and reinforces the necessity of timely diagnosis and treatment. While there have been advancements in treatment options, Jesy’s experience reflects a broader struggle for families dealing with this rare genetic condition. She emphasized the relentless nature of their medical journey and the emotional toll it has taken on her family, often feeling as though the hospital has become her second home. The struggle for increased awareness and improved treatment options remains ongoing in the fight against SMA, revealing the urgent need for families to be informed and equipped with the necessary knowledge to advocate for their children’s health. In conclusion, Jesy Nelson’s experience not only opens up a dialogue about the challenges faced by families of children with SMA but also stresses the importance of early detection and intervention. The urgency for healthcare systems to adapt and improve screening processes for rare genetic conditions like SMA is clearer than ever. By sharing her story, Jesy hopes to prevent other families from facing similar heartache and emphasizes the message that these conditions need to be taken seriously to allow for timely and effective care.

Spinal Muscular Atrophy (SMA) is a rare genetic disorder characterized by the degeneration of motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is primarily caused by mutations in the SMN1 gene, which is essential for the survival of motor neurons. The severity and onset of SMA can vary significantly among individuals, with the condition classified into different types based on the age of onset and the maximum motor function achieved. The most common and severe form, Type 1 SMA, typically presents in infancy and results in the inability to sit unaided. In contrast, Types 2 and 3 have later onset and allow for varying degrees of mobility and independence. Type 4 is the adult-onset form, characterized by milder symptoms and a slower progression of the disease. The incidence of SMA is estimated to be approximately 1 in 10,000 live births, making it one of the most common genetic causes of infant mortality. Though it affects all ethnic and racial groups, carriers of the SMN1 gene mutation are more prevalent among certain populations. SMA is inherited in an autosomal recessive manner, meaning that both parents must be carriers of the mutation for their child to be affected. Genetic testing can identify carriers and confirm a diagnosis in affected individuals, allowing for early intervention and management of the condition. Recent advancements in treatment options for SMA have significantly changed the outlook for individuals diagnosed with the condition. The introduction of disease-modifying therapies such as nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and rizugene socaparvovec (Evrysdi) has shown promise in improving motor function and extending survival rates. These therapies aim to increase the production of the SMN protein, which is deficient in SMA patients, thereby supporting motor neuron function. While these treatments have garnered attention due to their effectiveness, they also come with considerations regarding accessibility, cost, and potential side effects, necessitating a tailored approach to care for each patient. Comprehensive management of SMA also includes physical therapy, occupational therapy, and supportive care aimed at maximizing the patient’s quality of life. Multidisciplinary care teams are critical in addressing the complex needs of SMA patients, which can involve respiratory care, nutritional support, and psychosocial services. Ongoing research focuses on further understanding the pathophysiology of SMA, refining existing treatments, and exploring new therapeutic avenues. Awareness and education regarding SMA are also vital for early diagnosis and intervention, which can greatly affect long-term outcomes, underscoring the importance of genetic counseling for families at risk.